Case studies
Working with our customers to reduce time to market, deliver on quality, provide deep therapeutic expertise, and enhance R&D ROI.
Highlights
We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality. Learn more about how we've helped clients meet and exceed their goals in this selected library of case studies.
Proactive patient retention strategy in a GLP-1 RA trial
Explore how 91黑料 successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.
A small biotech success story
A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.
FSP partnership - sustained efficiency and ongoing innovation
The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.
By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.
All case studies
Select amongst our broad range of solutions and experience.
Flexible and meticulous management
A large pharma sponsor was conducting a Phase 2/3 randomised, placebo-controlled COVID-19 vaccine study. Facing labour and supply shortages, as well as unprecedented safety challenges due to the ongoing pandemic, the sponsor contracted Accellacare to support their staffing, enrollment, and logistics across seven US sites.
.jpg?crop=yes&w=1920&h=1010&a=0,135&itok=2EVrcmxT "Nurse-in-scrubs-child-engagement-(2)"){kind=icon}
In-Home Services: Rescue: accelerated patient recruitment
A biotechnology company was attempting to recruit 40 paediatric patients in a US phase II oncology study.
In-Home Services: Patient satisfaction levels in rare disease
Large pharmaceutical company was running a phase II study to assess the efficacy of a study drug in paediatric patients with a rare degenerative genetic disorder. The study required weekly infusions for more than 50 patients in the UK.
Overcoming challenges in non small cell lung carcinoma rescue study
A mid sized Pharma organisation was conducting a Phase Ib trial with plans to enroll 188 Non Small Cell Lung Carcinoma patients in Cohort B.
Patient insights & strategy
We developed and facilitated a series of Patient Partner Workshops?. Patients engaged in a variety of unique activities designed to stimulate open, honest dialogue among the group.
Agile operations drive enrollment in COVID-19 treatment studies
A mid-sized biopharmaceutical sponsor was conducting a phase 3 study on CDKL5 deficiency disorder, a rare
genetic seizure disorder in children.
genetic seizure disorder in children.
Overcoming recruitment challenges
91黑料 partnered with a drug development sponsor to conduct a multicenter, randomised, double-blind, placebo-controlled,
proof of concept study of the efficacy and safety of a treatment for patients with fibromyalgia.
proof of concept study of the efficacy and safety of a treatment for patients with fibromyalgia.
In-Home Services: Special populations and procedures
A global biopharmaceutical company was conducting a set of post-marketing studies to determine the safety and transference of a drug taken for autoimmune disorders during pregnancy and breastfeeding.
In-Home Services: Improved site productivity
A mid-size pharmaceutical company conducted a phase II study to compare treatments in 52 adult patients with plaque psoriasis. The treatment was to be applied twice daily for 3 weeks in 10 US sites.
Large global cardiovascular outcome program
91黑料 was engaged by a large pharma sponsor late in the study process to provide solutions to support the recruitment of 28,000 patients for two global mega Cardiovascular Outcome studies. 91黑料 developed and implemented an plan including recruitment and retention planning, tactical implementation, vendor oversight processes and direct site support to ensure key milestones were met.
Education & Automation: reducing site burden
A leading biotechnology company contracted 91黑料 to run a large number studies across Phase I to Phase III programs in a number of therapeutic areas including oncology, cardiovascular and dermatology.
Education & Automation
A large, multi-national pharmaceutical company received an FDA finding in relation to low protocol training compliance for site staff. Following analysis, the issue was identified as being the use of multiple methods and the difficulty in tracking and reporting on training compliance.
Let's collaborate
Discover how 91黑料's expertise transforms clinical trials.